Disseminated Fungal Infections in a Kidney Graft Transplant Recipient: Case Report and Literature Review.

Authors

  • Samuel Kabinga University of Nairobi, College Of Health Sciences, School of Medicine, P.O. BOX 30197 Postcode 00100 Nairobi, Kenya
  • Marybeth Maritim Kenyatta National Hospital, P.O. BOX 20723 Postcode 00202 Nairobi, Kenya
  • Daniel Zuriel
  • John Ngigi
  • Seth McLigeyo

Keywords:

Aspergillosis, Mucormycosis, kidney transplant recipient.

Abstract

We present a 61-year-old male, retired driver and a farmer from rural Kenya, East Africa, who had end-stage renal disease for 2 years with

References

Keskar, V.S., et al., Subcutaneous hyalohyphomycosis caused by Fusarium in a kidney transplant recipient. Ren Fail, 2014 Aug. 36(7): p. 1129-32.

Roden, M.M., T.E. Zaoutis, and W.L. Buchanan, Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 2005. 41(5): p. 634-53.

Lanternier, F., et al., Mucormycosis in Organ and Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2012. 54(11): p. 1629-36.

Liu, M., B. Spellberg, and Q.T. Phan, The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest, 2010. 120: p. 1914 - 24.

Windus, D.W., T.J. Stokes, and B.A. Julian, Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med, 1987. 107: p. 678 - 80.

Boelaert, J.R., M. deLocht, and J. VanCutsem, Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest, 1993. 91: p. 1979 - 86.

Trabelsi, H., et al., Invasive fungal infections in renal transplant recipients: about 11 cases. J Mycol Med, 2013 Dec. 23(4): p. 255-60.

Pappas, P.G., et al., Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis, 2010. 50 p. 1101-11.

Petrikkos, G., et al., Epidemiology and Clinical Manifestationsof Mucormycosis. Clin Infect Dis, 2012. 54(Suppl 1): p. S23-34.

Bialek, R. and U.E. Zelck, PCR-based diagnosis of mucormycosis in tissue samples. Pathologe, 2013 Nov. 34(6): p. 511-18.

Lanternier, F., et al., A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis, 2012. 54(1 Suppl): p. S35-43.

Ruping, M.J., et al., Forty-one recent cases of invasive zygomycosis from a globalclinical registry. J Antimicrob Chemother, 2010. 65(2): p. 296-302.

Skiada, A., et al., Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin. Microbiol Infect, 2011. 17(12): p. 1859-67.

Almyroudis, N.G., et al., Invitro susceptibilities of 217 clinical isolates of zygomycetes to conventionaland new antifungal agents. Antimicrob Agents Chemother. , 2007. 51(7): p. 2587-90.

Sabatelli, F., et al., In vitro activities of posaconazole, fluconazole, itraconazole,voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother., 2006. 50(6): p. 2009 -15.

Ballester, F., F.J. Pastor, and J. Guarro, Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother, 2008. 61(3): p. 755-7.

Perkhofer, S., et al., Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother., 2008. 52(7): p. 2636-8.

Walsh, T.J., E.J. Anaissie, and D.W. Denning, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis, 2008. 46: p. 327.

Upton, A., K.A. Kirby, and P. Carpenter, Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis, 2007. 44: p. 531.

Cornely, O.A., J. Maertens, and M. Bresnik, Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis, 2007. 44: p. 1289.

Diekema, D.J., S.A. Messer, and R.J. Hollis, Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi J Clin Microbiol 2003. 41: p. 3623.

Kuipers, S., et al., Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to Aspergillus fumigatus with Attenuated Susceptibility to Posaconazole. Antimicrob. Agents Chemother, 2011. 55(7): p. 3564

Robin, C., A. Alanio, and C. Cordonnier, Mucormycosis: a new concern in the transplant ward? Curr Opin Hematol, 2014 Nov. 21(6): p. 482-90.

Skiada, A. and G. Petrikkos, Cutaneous mucormycosis. Skinmed, 2013 May-Jun. 11(3): p. 155-9.

Godara, S.M., et al., Mucormycosis in renal transplant recipients: predictors and outcome. Saudi J Kidney Dis Transpl, 2011 Jul. 22(4): p. 751-6.

Segal, E., J.M.J. Menhusen, and S. Simmons, Hyperbaric Oxygen in the Treatment of Invasive Fungal Infections:A Single-Center Experience. IMAJ, 2007. 9: p. 355-7.

Downloads

Published

2016-01-10

How to Cite

Kabinga, S., Maritim, M., Zuriel, D., Ngigi, J., & McLigeyo, S. (2016). Disseminated Fungal Infections in a Kidney Graft Transplant Recipient: Case Report and Literature Review. International Journal of Sciences: Basic and Applied Research (IJSBAR), 25(1), 157–165. Retrieved from https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/5067

Issue

Vol. 25 No. 1 (2016)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.